EC approves expanded indication for BMS’ Sprycel

This article was originally published here

Bristol-Myers Squibb (BMS) has announced that the European Commission (EC) has expanded the indication for Sprycel (dasatinib) to include the treatment of children and adolescents aged 1 year to 18 years with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP), and to include a powder for oral suspension formulation.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply